Axsome Therapeutics (NASDAQ:AXSM) Given Buy Rating at

Dec 30, 2024 · Royal Bank of Canada boosted their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an "outperform" rating in a research note on Friday, …

$130.00
OFF

Axsome Therapeutics (NASDAQ:AXSM) Given Buy Rating At

2 weeks from now

Dec 30, 2024 · Royal Bank of Canada boosted their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an "outperform" rating in a research note on Friday, …

marketbeat.com

$121.00
OFF

Axsome Therapeutics’ (AXSM) Buy Rating Reiterated At Needham …

2 weeks from now

Jan 7, 2025 · Cantor Fitzgerald reaffirmed an “overweight” rating and set a $121.00 price target on shares of Axsome Therapeutics in a research note on Thursday, December 12th.

etfdailynews.com

$130.00
OFF

Buy Rating Affirmed For Axsome Therapeutics On Strong Pipeline …

2 weeks from now

Sep 5, 2024 · Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $130.00.. Ami Fadia has given his …

businessinsider.com

$121.00
OFF

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected To …

2 weeks from now

1 day ago · Cantor Fitzgerald reaffirmed an “overweight” rating and set a $121.00 price target on shares of Axsome Therapeutics in a research note on Thursday, December 12th.

etfdailynews.com

$180
OFF

Truist Raises Axsome Stock Target To $180, Maintains Buy Rating

2 weeks from now

5 days ago · On Friday, Truist Securities updated its outlook on Axsome Therapeutics (NASDAQ: AXSM), increasing the price target on the company’s stock to $180 from the previous target of …

investing.com

$180
OFF

Truist Raises Axsome Stock Target To $180, Maintains Buy Rating

2 weeks from now

5 days ago · On Friday, Truist Securities updated its outlook on Axsome Therapeutics (NASDAQ: AXSM), increasing the price target on the company's stock to $180 from the previous target of …

investing.com

$121.00
OFF

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating …

2 weeks from now

Dec 21, 2024 · AXSM has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $121.00 target price on shares of Axsome …

marketbeat.com

$124.00
OFF

Axsome Therapeutics (NASDAQ:AXSM) Earns "Buy" Rating From …

2 weeks from now

Jan 6, 2025 · Mizuho reduced their price objective on Axsome Therapeutics from $124.00 to $122.00 and set an "outperform" rating on the stock in a research note on Tuesday, December …

marketbeat.com

$125.00
OFF

Axsome Therapeutics (AXSM) Gets A Buy From TD Cowen

2 weeks from now

19 hours ago · In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $125.00. The …

businessinsider.com

$121.00
OFF

Pallas Capital Advisors LLC Purchases Shares Of 26,435 Axsome ...

2 weeks from now

2 days ago · Cantor Fitzgerald reaffirmed an "overweight" rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Truist …

marketbeat.com

$180
OFF

Truist Raises Axsome Therapeutics Target To $180, Maintains Buy

2 weeks from now

2 days ago · Analyst Ratings. Editor Lina Guerrero. Published 01/13/2025, 01:25 PM. ... AXSM-On Monday, Truist Securities adjusted its outlook on Axsome Therapeutics (NASDAQ: …

investing.com

$104
OFF

Truist Securities Raises Price Target On Axsome Therapeutics To …

2 weeks from now

4 days ago · Axsome Therapeutics, Inc., Q3 2024 Earnings Call, Nov 12, 2024 Nov. 12: Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q3 Revenue $104.8M Nov. 12: MT …

marketscreener.com

3%
OFF

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Up 5.3% On

2 weeks from now

2 days ago · Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report)'s share price rose 5.3% during trading on Monday after Truist Financial raised their price target on the stock from …

marketbeat.com

$125.00
OFF

TD Cowen Keeps Their Buy Rating On Axsome Therapeutics (AXSM)

2 weeks from now

Dec 30, 2024 · TD Cowen analyst Joseph Thome maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $125.00.The …

businessinsider.com

FAQs about Axsome Therapeutics (NASDAQ:AXSM) Given Buy Rating at Coupon?

Should you buy Axsome Therapeutics (axsm – research report)?

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $125.00. The company’s shares closed yesterday at $89.27. According to TipRanks, Thome is an analyst with an average return of -5.0% and a 37.95% success rate. ...

Is Axsome Therapeutics a good stock to buy?

Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $135.07, implying a 56.24% upside from current levels. In a report released on January 3, Morgan Stanley also assigned a Buy rating to the stock with a $125.00 price target. ...

Who is Axsome Therapeutics (axsm)?

Begin your TipRanks Premium journey today. Axsome Therapeutics (AXSM) Company Description: Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. ...

How much did Axsome Therapeutics (axsm) raise?

Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. ...

How did Axsome Therapeutics (axsm) perform in the quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. ...

How did Axsome Therapeutics perform compared to last year?

Based on Axsome Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $104.76 million and a GAAP net loss of $64.6 million. In comparison, last year the company earned a revenue of $57.79 million and had a GAAP net loss of $62.2 million ...